Clinical outcomes and cost-effectiveness of collaborative treatment with Korean and Western medicine in patients with facial palsy: a multicenter prospective observational study

Table 4 Mean variations in clinical outcomes by treatment group across study time points (PP)

Outcomes	Treatment group	Baseline		4 weeks			12 weeks			RM ANOVA
Outcomes	Treatment group	Mean	SD	Mean		SD	Mean	SD		Group	Time	Group x Time
HBGS	UC	3.40	1.01	2.17	1.19		1.83		0.85	0.132	< 0.001*	0.366
HBGS	CT	3.28	0.92	2.10	1.06		1.46		0.70	0.132	< 0.001*	0.366
NRS	UC	5.29	2.50	0.52	1.53		0.33		1.10	0.097	< 0.001*	0.251
NRS	CT	4.79	2.18	0.35	1.07		0.26		0.79	0.097	< 0.001*	0.251
EQ-5D-5L	UC	0.85	0.11	0.87	0.17		0.91		0.13	0.962	< 0.001*	0.044*
EQ-5D-5L	CT	0.81	0.12	0.88	0.13		0.94		0.11	0.962	< 0.001*	0.044*
EQ-VAS	UC	64.42	16.57	71.40	18.71		76.28		17.46	0.629	< 0.001*	0.074
EQ-VAS	CT	60.66	21.76	75.85	15.09		79.34		18.02	0.629	< 0.001*	0.074

UC, usual care; CT, collaborative treatment; HBGS, House-Brackmann grading scale; NRS, numeric rating scale; EQ-5D-5L, EuroQol-5 dimensions; EQ-VAS, EuroQol-visual analogue scale; RM ANOVA, repeated measures analysis of variance; SD, standard deviation; PP, per-protocol; *statistically significant at p < 0.05

ISSN: 2662-7671